Ordinary Rebalance | Solactive Pharma Breakthrough Value Index | Effective Date 18th March 2024
In the ordinary rebalance, the following composition will be implemented effective open 18.03.2024:
| ALNYLAM PHARMACEUTICALS INC |
| APELLIS PHARMACEUTICALS INC |
| ASTRAZENECA PLC-SPONS ADR |
| BAVARIAN NORDIC A/S |
| BEIGENE LTD-ADR |
| BIOCRYST PHARMACEUTICALS INC |
| BIOGEN INC |
| BIOMARIN PHARMACEUTICAL INC |
| BLUEBIRD BIO INC |
| CHUGAI PHARMACEUTICAL CO LTD ORD |
| CSL LTD ORD |
| DAIICHI SANKYO CO LTD ORD |
| EISAI |
| GENMAB A/S |
| GRIFOLS SA CLASS A |
| HALOZYME THERAPEUTICS INC |
| IDORSIA LTD |
| INCYTE CORP |
| INNOCARE PHARMA LTD |
| INNOVENT BIOLOGICS INC |
| IONIS PHARMACEUTICALS INC |
| IPSEN SA |
| JAZZ PHARMACEUTICALS PLC |
| JCR PHARMACEUTICALS CO LTD |
| JOHNSON & JOHNSON |
| KISSEI PHARMACEUTICAL CO ORD |
| KYOWA KIRIN CO LTD |
| MERCK & CO. INC. |
| NIPPON SHINYAKU CO LTD |
| NOVARTIS AG-ADR |
| PHARMA MAR SA |
| RECORDATI SPA |
| ROYALTY PHARMA PLC- CL A |
| SAREPTA THERAPEUTICS INC |
| SCICLONE PHARMACEUTICALS (HOLDINGS) LTD |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SWEDISH ORPHAN BIOVITRUM AB |
| TAKEDA PHARMACEUTICAL |
| ULTRAGENYX PHARMACEUTICAL INC |
| UNITED THERAPEUTICS CORP |
| VERTEX PHARMACEUTICALS INC |
| XENCOR INC |
| ZERIA PHARMACEUTICAL CO LTD |